Abstract
Advancing age is the greatest risk factor for developing multiple age-related diseases. When developing therapeutics, using a Geroscience approach to target the shared underlying pathways of ageing, rather than individual diseases, may be an effective way to treat and prevent age-related morbidity while potentially reducing the burden of polypharmacy. We harness the Open Targets Platform and Open Targets Genetics Portal to perform a systematic analysis of nearly 1,400 genome-wide association studies (GWAS) mapped to 34 age-related diseases and traits to identify genetic signals that appear to be shared between two or more of these traits. We identify 995 targets with shared genetic links to these age-related diseases and traits, which are enriched in mechanisms of ageing and include known ageing and longevity-related genes. Of these 995 genes, 128 are the target of an approved or investigational drug, 526 have experimental evidence of binding pockets or are predicted to be tractable by small molecule or antibody modality approaches, and 341 have no existing tractability evidence, representing underexplored genes which may reveal novel biological insights and therapeutic opportunities. We present these candidate targets in a web application, TargetAge, to enable the exploration and prioritisation of possible novel drug targets for age-related multimorbidity.
Competing Interest Statement
C.E.W. is now an employee of BenevolentAI. J.S. is now an employee of Illumina. M.K. is now an employee of Variant Bio. L.L. is now an employee of Ubiquigent Ltd.
Funding Statement
C.E.W., B.V., J.M.L., G.W., C.J.G. and L.L. are funded by the UK SPINE knowledge exchange network. B.M. is funded by the Kennedy Trust for Rheumatology Research. L.S. Acknowledges the support provided by the Sir Henry Wellcome fellowship [220457/Z/20/z]. M.K., M.J.F., J.S., D.O. and I.D. are funded by Open Targets. This research was funded in part by a Wellcome Trust [Grant number 206194]. For the purpose of Open Access, the authors have applied a CC-BY public copyright licence to any author-accepted manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that is available at https://genetics.opentargets.org/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in the study is publicly available, and all code and data produced in the study is available at https://github.com/CMD-Oxford/targetage-pipeline and https://github.com/CMD-Oxford/TargetAgeApp
